With reports emerging of vaccine wastage across the world, medical supply chain experts explain why that's to be expected.
Jan. 11, 2021 • ~8 min
covid-19 supply-chains astrazeneca pfizerbiontech-vaccine vaccine-distribution vaccine-roll-out covid-vaccine
With vaccine shortages looming, experts are debating whether it is important to receive two doses or whether it's better to give one dose to more people and give a second when the supply is better.
Jan. 11, 2021 • ~11 min
covid-19 coronavirus immune-system pandemic t-cells antibodies sars-cov-2 moderna astrazeneca pfizerbiontech-vaccine
Researchers say around 70% of the US needs to get the coronavirus vaccine to stop the pandemic. But questions around the vaccines and regional differences add some uncertainty to that estimate.
Jan. 5, 2021 • ~8 min
covid-19 coronavirus transmission vaccines immunity population herd-immunity viruses pfizer moderna astrazeneca
The top scientific breakthrough for 2020 was understanding SARS-CoV-2 and how it causes COVID-19 – and then developing multiple vaccines
The development of multiple vaccines against the virus that causes COVID-19 has been hailed as the breakthrough of 2020. But there were many more supporting discoveries that made this possible.
Dec. 17, 2020 • ~11 min
innovation genome covid-19 immune-system pandemic vaccines sars-cov-2 remdesivir drug-development monoclonal-antibodies astrazeneca pfizerbiontech-vaccine moderna-vaccine pfizer-vaccine
The vaccines that will first be used to prevent the spread of COVID-19 will have gone through a special approval process with the FDA. but just what is this expedited process?
Dec. 3, 2020 • ~10 min
covid-19 coronavirus fda vaccines coronavirus-vaccine pfizer aids moderna emergency-use-authorization astrazeneca covid-19-vaccines eua fda-drug-approval-process
Oxford-AstraZeneca vaccine is cheaper than Pfizer's and Moderna's and doesn't require supercold temperature
There is now a third vaccine that prevents COVID-19 infections. It isn't quite as effective as the other two vaccines but it has advantages that may make it the frontrunner.
Nov. 24, 2020 • ~9 min
covid-19 immune-system pandemic vaccines sars-cov-2 antibody university-of-oxford astrazeneca covid-19-vaccines pfizerbiontech-vaccine moderna-vaccine pfizer-vaccine
With COVID-19 cases soaring across the US and worldwide, the need for a vaccine could not be greater. With some half-dozen vaccines in phase 3 trials, why wasn't one ready before Election Day?
Nov. 10, 2020 • ~9 min
covid-19 coronavirus pandemic rna vaccines pfizer moderna emergency-use-authorization astrazeneca